Literature DB >> 22876027

Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease.

Luca Valenti1, Paola Dongiovanni, Silvia Fargion.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), defined by excessive liver fat deposition related to the metabolic syndrome, is a leading cause of progressive liver disease, for which accurate non-invasive staging systems and effective treatments are still lacking. Evidence has shown that increased ferritin levels are associated with the metabolic insulin resistance syndrome, and higher hepatic iron and fat content. Hyperferritinemia and iron stores have been associated with the severity of liver damage in NAFLD, and iron depletion reduced insulin resistance and liver enzymes. Recently, Kowdley et al demonstrated in a multicenter study in 628 adult patients with NAFLD from the NAFLD-clinical research network database with central re-evaluation of liver histology and iron staining that the increased serum ferritin level is an independent predictor of liver damage in patients with NAFLD, and is useful to identify NAFLD patients at risk of non-alcoholic steatohepatitis and advanced fibrosis. These data indicate that incorporation of serum ferritin level may improve the performance of noninvasive scoring of liver damage in patients with NAFLD, and that iron depletion still represents an attractive therapeutic target to prevent the progression of liver damage in these patients.

Entities:  

Keywords:  Ferritin; Fibrosis; Iron overload; Nonalcoholic fatty liver disease; Steatohepatitis; Steatosis

Mesh:

Substances:

Year:  2012        PMID: 22876027      PMCID: PMC3413047          DOI: 10.3748/wjg.v18.i29.3782

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  Association between serum ferritin, hemoglobin, iron intake, and diabetes in adults in Jiangsu, China.

Authors:  Zumin Shi; Xiaoshu Hu; Baojun Yuan; Xiaoqun Pan; Haakon E Meyer; Gerd Holmboe-Ottesen
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

2.  Association between serum ferritin and the insulin resistance syndrome in a representative population.

Authors:  C E Wrede; R Buettner; L C Bollheimer; J Schölmerich; K-D Palitzsch; C Hellerbrand
Journal:  Eur J Endocrinol       Date:  2006-02       Impact factor: 6.664

3.  Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.

Authors:  Paolo Sorrentino; Salvatore D'Angelo; Umberto Ferbo; Pietro Micheli; Alessandra Bracigliano; Raffaela Vecchione
Journal:  J Hepatol       Date:  2008-11-14       Impact factor: 25.083

Review 4.  Macrophage iron, hepcidin, and atherosclerotic plaque stability.

Authors:  Jerome L Sullivan
Journal:  Exp Biol Med (Maywood)       Date:  2007-09

5.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

6.  Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Paola Dongiovanni; Elisabetta Bugianesi; Giulio Marchesini; Paola Manzini; Ester Vanni; Silvia Fargion
Journal:  Am J Gastroenterol       Date:  2007-03-27       Impact factor: 10.864

7.  ER stress controls iron metabolism through induction of hepcidin.

Authors:  Chiara Vecchi; Giuliana Montosi; Kezhong Zhang; Igor Lamberti; Stephen A Duncan; Randal J Kaufman; Antonello Pietrangelo
Journal:  Science       Date:  2009-08-14       Impact factor: 47.728

8.  Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver.

Authors:  Paola Dongiovanni; Luca Valenti; Anna Ludovica Fracanzani; Stefano Gatti; Gaetano Cairo; Silvia Fargion
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

9.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Authors:  Anna Ludovica Fracanzani; Luca Valenti; Elisabetta Bugianesi; Marco Andreoletti; Agostino Colli; Ester Vanni; Cristina Bertelli; Erika Fatta; Daniela Bignamini; Giulio Marchesini; Silvia Fargion
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

10.  Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study.

Authors:  N G Forouhi; A H Harding; M Allison; M S Sandhu; A Welch; R Luben; S Bingham; K T Khaw; N J Wareham
Journal:  Diabetologia       Date:  2007-03-02       Impact factor: 10.122

View more
  21 in total

1.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Paola Dongiovanni; Serena Rovida; Raffaela Rametta; Erika Fatta; Edoardo Alessandro Pulixi; Marco Maggioni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.

Authors:  Pathik Parikh; Jatin Patel; Meghraj Ingle; Prabha Sawant
Journal:  Indian J Gastroenterol       Date:  2015-06-25

4.  Pharmacological agents for nonalcoholic steatohepatitis.

Authors:  Maeva Guillaume; Vlad Ratziu
Journal:  Hepatol Int       Date:  2013-11-19       Impact factor: 6.047

Review 5.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 6.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 7.  Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.

Authors:  Kuang-Chun Hu; Horng-Yuan Wang; Sung-Chen Liu; Chuan-Chuan Liu; Chung-Lieh Hung; Ming-Jong Bair; Chun-Jen Liu; Ming-Shiang Wu; Shou-Chuan Shih
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 8.  Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets.

Authors:  Long-Xia Li; Fang-Fang Guo; Hong Liu; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2022-03-24       Impact factor: 9.261

9.  The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Raffaela Rametta; Paola Dongiovanni; Benedetta M Motta; Elena Canavesi; Serena Pelusi; Edoardo A Pulixi; Anna L Fracanzani; Silvia Fargion
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

10.  Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy.

Authors:  Ashraf Soliman; Mohamed Yassin; Fawzia Al Yafei; Lolwa Al-Naimi; Noora Almarri; Aml Sabt; Vincenzo De Sanctis
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.